3 results
Search Results
2. Signals from the TAFA4-PTEN-PU.1 axis alleviate nasal allergy by modulating the expression of FcεRI in mast cells.
- Author
-
Zhou, Caijie, Li, Meihua, Liu, Yu, Wang, Xinxin, Zhang, Shuang, Guan, Li, Hong, Jingyi, Zhou, Wei, Wu, Gaohui, Diao, Weiliang, Huang, Qinmiao, and Yang, Pingchang
- Subjects
MAST cells ,AUTOREGRESSIVE models ,ALLERGIC rhinitis ,ALLERGIES ,TRYPTASE - Abstract
The high-affinity IgE receptor, FcεRI, plays a key role in the antigen-induced mast cell activation. Regulations for FcεRI are not yet well understood. TAFA4 is a molecule derived from neuron tissues, and has immune regulation functions. This study aims to clarify the role of TAFA4 in the regulation of FcεRI expression in mast cells. Nasal secretions were collected from patients with allergic rhinitis (AR) and healthy control (HC) subjects. TAFA4 levels of nasal secretions were evaluated by ELISA. A mouse model AR was developed using ovalbumin as the specific antigen. Negative correlation between TAFA4 and tryptase levels in nasal secretions was observed. TAFA4 could suppress the antigen-related mast cell activation. TAFA4 modulated the transcription of Fcer1g (FcεRI γ gene) in mast cells. Signals from the TAFA4-PTEN-PU.1 axis restricted FcεRI expression in mast cells. Administration of TAFA4 attenuated experimental AR. TAFA4 suppressed the expression of FcεRI in mast cells of airway tissues. TAFA4 can down regulate the expression of FcεRI in mast cells to suppress experimental AR. The data suggest that TAFA4 has translation potential to be developed as an anti-allergy therapy. TAFA4 suppressed the expression of FceRI in mast cells of airway tissues. Signals from the TAFA4-PTEN-PU.1 axis restricted FceRI expression in mast cells. Administration of TAFA4 attenuated experimental AR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients.
- Author
-
Wang, Yuting, Niu, Xiaomin, Cheng, Yirui, Zhang, Yanshuang, Xia, Liliang, Xia, Weiliang, and Lu, Shun
- Subjects
PROGRAMMED death-ligand 1 ,EXOSOMES ,IMMUNE checkpoint inhibitors ,NON-small-cell lung carcinoma ,ENZYME-linked immunosorbent assay - Abstract
Immune Check-Point Inhibitors (ICIs) have shown remarkable promise in treating tumors, including non-small cell lung cancer (NSCLC). Nevertheless, the treatment response rate is low. Studies have found that the high expression of exosomal PD-L1 is one of the reasons for the low treatment response. Therefore, this study focused on the relationship between the exosomal PD-L1 and the clinical response to immunotherapy in NSCLC patients to evaluate whether it could be used as a biomarker to predict the efficacy of ICIs. In this study, clinical information and blood samples of 149 NSCLC patients receiving ICIs were collected. The expression level of exosomal PD-L1 was detected by enzyme-linked immunosorbent assay method, and the relationship between exosomal PD-L1 and the efficacy of ICIs was explored. Overall, our study found that the expression level of exosomal PD-L1 was lower at pre-treatment, or the max fold increasing change higher at 3–6 weeks had a higher disease control rate and longer progression-free survival. It revealed that the exosomal PD-L1 was associated with the treatment response of patients using ICIs and provided a new tool for the evaluation of clinical efficacy of lung cancer immunotherapy. This study revealed that exosomal PD-L1 was associated with the treatment response of patients using ICIs. The level of pre-treatment and the maximum fold increasing change of exosomal PD-L1 stratified clinical responders and non-responders. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.